AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-26. Anything still debated is marked as such rather than presented as settled.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Structures that are intraperitoneal are generally mobile, while those that are retroperitoneal are relatively fixed in their location. Some structures, such as the kidneys, are "primarily retroperitoneal", while others such as the majority of the duodenum, are "secondarily retroperitoneal", meaning that structure developed intraperitoneally but lost its mesentery and thus became retroperitoneal.
== Human pathogenicity == Species within the genus Penicillium do not generally cause disease in humans. However, being one of the most common producers of indoor moulds, certain species can become pathogenic upon long-term exposure, as well as for individuals who are immunocompromised or hyper-sensitized to certain parts of the fungus. Spores, proteolytic enzymes, and glycoproteins are amongst the components commonly reported as allergens in humans and animal models. Within this context, members of Penicillium have been associated with a variety of immunological manifestations such as Type 1 allergic responses, hypersensitivity pneumonitis (Type 3 responses), and immediate and delayed asthma. With respect to P. digitatum, this species is known to cause a generalized fungal infection (mycosis) in humans, although the incidence of such events is very low. Various studies have also noted a presence of circulating antibodies to the extracellular polysaccharide of P. digitatum, in both human and rabbit sera. This presence is suggested to be due to the intake of contaminated fruits and/or breathing air contaminated with extracellular polysaccharide. In terms of allergy testing, P. digitatum is present in various clinical allergy test formulations, testing for allergy to moulds. There has been one case report identifying P. digitatum as the cause of a fatal case of pneumonia, via molecular methods.
Tyne and Wear is divided into 12 parliamentary constituencies. Historically, the area has been a Labour stronghold; South Shields is the only Parliamentary constituency that has never returned a Conservative Member of Parliament (MP) to the House of Commons since the Reform Act of 1832.
Some quantum dots pose risks to human health and the environment under certain conditions. Notably, the studies on quantum dot toxicity have focused on particles containing cadmium and have yet to be demonstrated in animal models after physiologically relevant dosing. In vitro studies, based on cell cultures, on quantum dots (QD) toxicity suggest that their toxicity may derive from multiple factors including their physicochemical characteristics (size, shape, composition, surface functional groups, and surface charges) and their environment. Assessing their potential toxicity is complex as these factors include properties such as QD size, charge, concentration, chemical composition, capping ligands, and also on their oxidative, mechanical, and photolytic stability. Many studies have focused on the mechanism of QD cytotoxicity using model cell cultures. It has been demonstrated that after exposure to ultraviolet radiation or oxidation by air, CdSe QDs release free cadmium ions causing cell death. Group II–VI QDs also have been reported to induce the formation of reactive oxygen species after exposure to light, which in turn can damage cellular components such as proteins, lipids, and DNA. Some studies have also demonstrated that addition of a ZnS shell inhibits the process of reactive oxygen species in CdSe QDs.
Sources: en.wikipedia.org
Maddy Parsons is a British cell biologist who is a professor and Associate Dean for Impact & Innovation at King's College London. She is the Director of the Nikon Imaging Centre. Her research looks to understand the fundamental mechanisms that underpin cell adhesion and migration. She is Chair of the Medical Research Council Molecular & Cellular Medicine Board.
=== Wastewater treatment === A majority of silver nanoparticles in consumer products go down the drain and are eventually released into sewer systems and reach wastewater treatment plants. Primary screening and grit removal in wastewater treatment does not completely filter out silver nanoparticles, and coagulation treatment may lead to further condensation into wastewater sludge. The secondary wastewater treatment process involves suspended growth systems which allow bacteria to decompose organic matter within the water. Any silver nanoparticles still suspended in the water may collect on these microbes, potentially killing them due to their antimicrobial effects. After passing through both treatment processes, the silver nanoparticles are eventually deposited into the environment. A majority of the submerged portions of wastewater treatment plants are anoxic and rich in sulfur. During the wastewater treatment process, silver nanoparticles either remain the same, are converted into free silver ions, complex with ligands, or agglomerate. Silver nanoparticles can also attach to wastewater biosolids found in both the sludge and the effluent. Silver ions in wastewater are removed efficiently because of their strong complexation with chloride or sulfide. A majority of the silver found in wastewater treatment plant effluent is associated with reduced sulfur as organic thiol groups and inorganic sulfides. Silver nanoparticles also tend to accumulate in activated sludge, and the dominant form of the silver found in sewage sludge is Ag2S.
Day of Defeat's initial retail offering included fifteen maps, each depicting different scenarios with variation in size and thematic locations. These often drew inspiration from historical World War II battles, such as the battle at Omaha Beach and street-fighting in the Italian city of Salerno during Operation Avalanche. The game also features a Glider mission wherein the American 101st Airborne lands in a WACO Glider and destroys such objectives as a radio antenna and Flak 88 mm gun anti-aircraft gun. Weapons in the game are also of historical significance, with much of the weaponry being accurate representations of those used in World War II. The weapon selection is also realistic in its usage, with recoil and accuracy representative of the gun's real-life counterparts.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.